The US FDA approved Pfizer's Hympavzi on Monday for children aged 6 to 11 with hemophilia, making it the first non-factor therapy cleared for this age group with or without inhibitors. The drug prevents or reduces bleeding episodes in pediatric patients, expanding options beyond traditional factor replacement.

Side effects: potential concerns remain under monitoring as real-world use expands.

Refills

Cancer breakthroughs from ASCO — New data on pancreatic...